Insider Ledger
MBRX insider buying and SEC filings, explained
Moleculin Biotech, Inc. · CIK 1659617
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 3, 2026 | Other purchase | Jonathan P. Foster (CFO) bought 1,173,332 shares in 2 share classes; the filing does not report a price. Holdings of Series I Warrants up 596% to 1,027,717 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 5, 2026 |
| Aug 3, 2026 | Other purchase | Walter V. Klemp (CEO and Director) bought 533,333 shares; the filing does not report a price. Holdings up 999%+ to 564,340 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 5, 2026 |
| Aug 3, 2026 | Other purchase | Donald H. Picker (Chief Science Officer) bought 693,332 shares in 2 share classes; the filing does not report a price. Holdings of Series I Warrants up 999%+ to 539,595 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 5, 2026 |
18 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Oct 30, 2026, 8:50 AM ET 8-K | Reg FD disclosure (Item 7.01) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow MBRX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.